Glucose Transporter Type 1
"Glucose Transporter Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitously expressed glucose transporter that is important for constitutive, basal GLUCOSE transport. It is predominately expressed in ENDOTHELIAL CELLS and ERYTHROCYTES at the BLOOD-BRAIN BARRIER and is responsible for GLUCOSE entry into the BRAIN.
| Descriptor ID |
D051272
|
| MeSH Number(s) |
D12.776.157.530.500.500.500 D12.776.157.530.937.563.500 D12.776.543.585.500.500.500 D12.776.543.585.937.625.500
|
| Concept/Terms |
Glucose Transporter Type 1- Glucose Transporter Type 1
- GLUT-1 Protein
- GLUT 1 Protein
- Solute Carrier Family 2, Facilitated Glucose Transporter, Member 1 Protein
- SLC2A1 Protein
- GLUT1 Protein
- Erythrocyte Glucose Transporter
- Glucose Transporter, Erythrocyte
|
Below are MeSH descriptors whose meaning is more general than "Glucose Transporter Type 1".
Below are MeSH descriptors whose meaning is more specific than "Glucose Transporter Type 1".
This graph shows the total number of publications written about "Glucose Transporter Type 1" by people in this website by year, and whether "Glucose Transporter Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucose Transporter Type 1" by people in Profiles.
-
Transient Intermittent Hyperglycemia Accelerates Atherosclerosis by Promoting Myelopoiesis. Circ Res. 2020 09 11; 127(7):877-892.
-
p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Rep. 2019 08 13; 28(7):1860-1878.e9.
-
Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics. J Theor Biol. 2019 03 21; 465:117-125.
-
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun. 2017 05 26; 8:15503.
-
The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. Breast Cancer Res. 2016 12 20; 18(1):131.
-
The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014 Jul 01; 20(1):61-72.
-
Activation of serum/glucocorticoid-induced kinase 1 (SGK1) underlies increased glycogen levels, mTOR activation, and autophagy defects in Lafora disease. Mol Biol Cell. 2013 Dec; 24(24):3776-86.
-
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 2013 Mar 01; 132(5):1201-12.
-
Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011; 6(8):e23205.
-
Prolactin-mediated regulation of lipid biosynthesis genes in vivo in the lactating mammary epithelial cell. Am J Physiol Endocrinol Metab. 2011 Jun; 300(6):E1059-68.